ModernMedicine Resource Center More Topics

DME Resource Center

Tie2 activator augments anti-VEGF for DMEResults from TIME-2, a phase IIA study, support further development of combination treatment with subcutaneous injection of the Tie2 activator, AKB-9778 (Aerpio Therapeutics), plus intravitreous (IVT) anti-VEGF injection for diabetic macular edema.
DME therapy with plasma kallikrein inhibitor showing promiseResults from a phase I study of KVD001 (KalVista Pharmaceuticals) for the treatment of central involved diabetic macular edema (CIDME) show that this plasma kallikrein inhibitor was well-tolerated, not associated with any ophthalmic or systemic safety signals, and led to fairly long-lasting improvements in visual acuity (VA) and central retinal thickness (CRT) after a single intravitreous injection.
Diabetic retinopathy and macular oedema increase in SpainDiabetic retinopathy and diabetic macular oedema are both increasing in Spain, especially among relatively young people, researchers said.
Latest concepts in steroid therapy for diabetic macular oedemaSteroids are an important second-line treatment for the treatment of diabetic macular oedema. While side effects remain a concern, modern formulations of intravitreal steroid allow the treatment to be tailored to the individual patient.
Steroids may be preferable to anti-VEGF for DME in certain casesTwo-year study results highlight some advantages of steroid treatment for DME.
Investigational pipeline for DME looks promisingPharmacotherapy research for diabetic macular edema is looking at targets other than VEGF inhibition to develop treatments that can be used as standalone intervention or may be complementary to current options.
Anti-VEGF patterns of use for DME may vary in clinical practiceThough anti-vascular endothelial growth factor therapy for diabetic macular edema showed impressive results in trials, clinicians have reported less success on their own.
PKal May Join VEGF as DME pathwayA protein called PKal (plasma kallikrein) and its associated molecules are key players in an inflammatory molecular pathway involved in diabetic macular edema, according to a study published in Diabetes.
Prior vitrectomy does not affect DME therapy with ranibizumab, laserAnalysis of eyes with and without prior vitrectomy from DRCR Protocol I showed similar results when treated with ranibizumab with prompt or deferred laser.
Intravitreal sirolimus shows promise for noninfectious posterior segment uveitisSAKURA is a 24-month phase III study investigating the efficacy and safety of intravitreal sirolimus for treatment of noninfectious posterior segment uveitis. Data were reported from the primary endpoint visit at 5 months.